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Summary A sensitive single-stranded hybridisation probe for the oestrogen receptor mRNA was synthesised
using T3 polymerase from oestrogen receptor cDNA cloned in the Bluescript vector. This probe was used to
measure oestrogen receptor mRNA in total RNA extracted from breast tumours. Oestrogen receptor mRNA
was detected in 41 of 47 (87%) tumours whereas cytosolic oestrogen receptor protein was detected in only 18
out of 39 (46%). There was a significant correlation between the levels of the oestrogen receptor, as measured
by 3H-oestradiol binding, and the oestrogen receptor mRNA. Oestrogen receptor mRNA was detected in 15
of the 21 tumours that did not contain detectable oestrogen receptor protein. This suggests that detection of
the mRNA is a more sensitive means for establishing oestrogen receptor status than the radioligand oestrogen
receptor assay. Oestrogen receptor m,RNA was found in all histological tumour types examined. Its level was
related to tumour differentiation. All the tumours that did not contain oestrogen receptor mRNA and most
of the tumours that contained only low levels of oestrogen receptor mRNA were classified as grade III
according to Bloom and Richardson: the median of the oestrogen receptor mRNA levels was significantly
lower in this group.
Breast cancer has long been known to be oestrogen respon-
sive and the expression of the oestrogen receptor in a
proportion of tumours is well recognised (McGuire et al.,
1975). Different studies find the proportion of breast
tumours expressing oestrogen receptor to be variable, rang-
ing from 60% to 80% (Hawkins, 1985). Most studies
indicate that patients with oestrogen receptor-positive
tumours have better disease-free, post-relapse and overall
survival, compared to those with oestrogen-receptor negative
tumours (reviewed by Hawkins, 1985). A higher proportion
of oestrogen receptor-positive tumours respond to anti-
oestrogen therapy: paradoxically, a small number of oestro-
gen receptor-negative tumours also respond (Desombre et
al., 1978).
A variety of technique' have been used to determine
oestrogen receptor protein levels in breast tumours, including
tritiated hexoestrol binding in vivo (Folca, 1961), sedimen-
tation assays (Desombre et al., 1978), dextran-coated char-
coal assays (Korenman & Dukes, 1970), radio-immunoassay
(Thorpe, 1987) and immunocytochemistry (Coombes et al.,
1987). The recent isolation and cloning of the oestrogen
receptor cDNA by Walter et al. (1985) has now made it
possible to study oestrogen receptor mRNA expression. Parl
et al. (1987) demonstrated oestrogen receptor mRNA in
extracts of human uterus and Barrett-Lee et al. (1987) used
dot-blots to quantify oestrogen receptor mRNA in a series
of human breast tumour extracts. We describe here the
detection of mRNA for the oestrogen receptor in a series of
47 breast cancer samples by hybridisation to northern
transfers with a sensitive single-stranded RNA probe.
Materials and methods
Breast tumours comprising 39 primary ductal carcinomas, 3
lymph node metastases of ductal carcinomas (one from a
primary ductal carcinoma also extracted), 1 recurrent ductal
carcinoma (from a primary carcinoma already extracted), 1
mucinous ductal carcinoma, 2 lobular carcinomas and 1
atypical medullary carcinoma were obtained fresh. Suitable
tumour tissue for RNA extraction was selected and imme-
diately stored in liquid nitrogen: sample weight varied from
0.3 g to I g. Adjacent tumour tissue was examined histo-
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logically. RNA was also prepared from combined endo-
metrium and myometrium from the uterus of a
premenopausal woman. Patient age ranged from 24 to 95
years: 14 were less than 50 years old and considered to be
premenopausal.
RNA extraction
RNA was extracted from the 47 tumour biopsies and the
uterus using a modification of the method of Auffrey &
Rougeon (1980). Tumours frozen in liquid nitrogen were
reduced to a powder using a Braun mikro dismembrator.
Tumour powder was transferred to a Corex centrifuge tube,
suspended in 5ml of 3M LiCl, 6M urea, 0.5% SDS and
50mM sodium acetate (pH5.6) and the DNA was sheared
with an Ultraturrax homogeniser. RNA was precipitated at
4°C for 18h and recovered by centrifugation at 10,OOOg for
20min. The supernatant was discarded and the resultant
pellet was washed in 3 ml of 3 M LiCl, 6 M urea and 50mM
sodium acetate and recentrifuged at 10,000g for 0 min. The
pellet was then resuspended in 1.125ml lOmM Tris buffer
pH 8.0, 0.2% SDS, at room temperature, Tris buffer pH 8.0
and EDTA were added to 0.1 M and 5mM, respectively in
1.25ml total volume and then extracted with phenol:chloro-
form (50:50) and chloroform:isoamyl alcohol (24:1). The
organic phases were back extracted with 1.25ml 100mM
Tris pH9. Following the addition of 6.25ml 100% ethanol
and 50pl 5 M NaCl, RNA was precipitated at -20°C. After
centrifugation, the pellet was washed in 70% cold ethanol,
recentrifuged, dried and finally redissolved in 10mM Tris,
0.2% SDS pH 8. Total RNA yields were estimated from the
optical density at 260nm. MCF-7 cell RNA was prepared as
described previously (May and Westley, 1986).
Electrophoresis and transfer of RNA
RNA samples (1Ojug) were denatured for 10min at 65"C in
50% dimethylsulphoxide, 2.2 M formaldehyde, 10mM
sodium phosphate (pH 7.5), 0.5 mM EDTA and then electro-
phoresed through a 1.2% agarose gel containing 2.2 M
formaldehyde in 1OmM sodium phosphate (pH7.5) for 500
volt-hours. After 30 min staining in ethidium bromide the
RNA was visualised by UV transillumination and the inte-
grity of the RNA assessed. Following two 30min equili-
brations in 20 x SSC (3.0 M NaCI; 0.3 M Na Citrate) the
RNA was transferred to nitrocellulose or hybond-N filtes
(Amersham, UK) by the method of Southern (1975). Nitro-
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cellulose filters were baked under vacuum for 4h at 80°C
and hybond-N filters were dried at 80°C for 30min and then
the RNA covalently fixed to the membrane by irradiation
with UV light (310nm) for 5min.
Probe synthesis and hybridisation
The oestrogen receptor cDNA (pOR3) cloned in pBR 322
(Walter et al., 1985) was labelled with 32P-dCTP by nick-
translation to a specific activity of 5x 108 cpm jug -. Filters
were hybridised with 4 x 106 cpmml-1 in a solution con-
taining 50% formamide for 3 days as described previously
(Westley & May, 1984). The oestrogen receptor cDNA was
subcloned into the commercially available Stratagene Blue-
script vector (obtained from Northumbria Biologicals, South
Nelson Industrial Estate, Cramlington, Northumberland).
The multiple cloning site contained within this vector is
flanked by promoters for T3 and T7 RNA polymerases.
Radiolabelled probes were synthesised by transcription and
hybridised at 107cpmml-1 to the hybond-N filters at 65°C
for 72h as described previously (May & Westley, 1987).
After extensive washing in 0.1 x SSC at 80°C the filters were
exposed to preflashed X-ray film at -70°C. The extent of
hybridisation of the radiolabelled probe was determined by
scanning densitometry and integration of the area under the
peak. The amount of hybridised oestrogen receptor RNA
was expressed in arbitrary units relative to the amount
hybridising to 10,ug of MCF-7 cell total RNA.
Oestrogen receptor assay
For some of the tumours, the cytoplasmic oestrogen receptor
content was measured in a slice of tumour adjacent to the
piece from which RNA was extracted. The dextran-coated
charcoal method was used with seven concentrations of
tritium-labelled oestradiol 17-,B (Leake et al., 1981); results
were obtained by Scatchard analysis of the binding data.
Tumours with oestrogen receptor levels greater than
5 fmolmg 1 protein were considered positive. The reproduci-
bility and quality of this assay is ascertained by participation
in the British Steroid Receptor Quality Control Scheme.
Results
Preparation of a sensitive RNA probe for the
oestrogen receptor
The availability of cloned cDNA probes for the oestrogen
receptor should allow measurement of the oestrogen receptor
mRNA levels in breast tumour samples. The ability to
measure oestrogen receptor mRNA in total rather than
poly(A)+ RNA would facilitate routine assay by avoiding
mRNA purification. To determine the sensitivity of hybridis-
ation with a cDNA probe, the oestrogen receptor cDNA was
nick-translated and hybridised to Northern transfers of 10,ug
total RNA prepared from several human breast cancer cell
lines known to contain the oestrogen receptor protein (Red-
dell et al., 1985). A very weak hybridisation signal was
detected to an RNA of 6.2kb in RNA prepared from the
EFM-19 cell line (Simon et al., 1984); no hybridisation was
detected to RNA from the MCF-7, T47D, or ZR-75 cell
lines (data not shown). Therefore, to measure different levels
of oestrogen receptor mRNA in total RNA preparations, it
was necessary to increase the sensitivity above that obtained
with the nick-translated probe.
An Eco RI fragment of the oestrogen receptor cDNA was
isolated and subcloned into the Bluescript vector. The multi-
ple cloning site contained within this vector is flanked by
promoters for T3 and T7 RNA polymerases that permit
transcription of high specific activity, single-stranded RNA
probes from the cDNA insert (Figure 1; Melton et al., 1984).
As the orientation of the oestrogen receptor cDNA was
unknown, we were unable to predict from which end the
RNA probe should be synthesised. The construct was there-
fore linearised with Bam HI and RNA transcribed from the
T3 promoter (as shown in Figure 1), or with Sal 1 and RNA
transcribed from the T7 promoter.
The two radiolabelled probes were hybridised to total
RNA prepared from MCF-7 cells. Ten ,ug total RNA was
electrophoresed through a denaturing agarose gel, trans-
ferred to nitrocellulose and hybridised with the probes. The
autoradiographs obtained are shown in Figure 2, alongside
the result obtained with the nick-translated cDNA probe for
the oestrogen receptor. Strand-specific hybridisation to an
RNA of 6.2kb was obtained with the RNA initiated from
the T3 promoter. This agrees with the results reported by
Walter et al. (1985) who detected a 6.2kb RNA in 30,ug
poly A+ RNA prepared from MCF-7 and T47D cells using
a nick-translated oestrogen receptor cDNA probe.
Oestrogen receptor RNA in breast tumour specimens
RNA was prepared from 47 breast tumour specimens and a
uterus from a premenopausal woman. The weight of the
tumour samples ranged from 0.3 g to 1 g and the total RNA
yield varied from 54jg to 940jpg. Agarose gel electrophoresis
of these extracts revealed good quality RNA with most
preparations showing only slight degradation as judged by
the ratio of 28S to 18S RNA. In some instances, histo-
logically observed tumour necrosis may explain the RNA
degradation.
Ten jug of total RNA were denatured, electrophoresed on
formaldehyde-containing agarose gels, transferred to a nylon
membrane and hybridised with the single-stranded oestrogen
receptor RNA probe. To quantify the hybridisation
obtained, the autoradiographic signals were measured by
scanning densitometry and integration of the area under the
resultant peak. Oestrogen receptor mRNA levels were
expressed as Arbitrary Units (AU), one arbitrary unit being
equal to 5% of the amount of oestrogen receptor RNA
present in lOg MCF-7 RNA. These MCF-7 cells contain
l100fmol oestrogen receptor mg-' cytosolic protein.
Examples of selected results from different tissues are
shown in Figure 3. Hybridisations to different concentrations
of the RNA from MCF-7 cells are shown to the left of the
figure and to 10 g RNA from the uterus of a premeno-
pausal woman on the right of the figure for comparison.
Ampicillin resistance
f-galactosidase
RNA transcript
Figure I Structure of Bluescript oestrogen receptor cDNA
recombinant. An Eco RI fragment of the oestrogen receptor
cDNA was cloned into Bluescript (KSM13-) at the Eco RI site.
An RNA probe for the oestrogen receptor mRNA was synthe-
sised using T3 polymerase and Bam HI linearised DNA. The
direction of RNA synthesis, the positions of 5 restriction sites in
the multiple cloning site, the positions of the T3 and T7
promoters, the ,B-galactosidase and ampicillin resistance genes are
marked.602 J.A. HENRY et al.
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Figure 2 Hybridisation of oestrogen receptor probes to North-
ern transfers of MCF-7 RNA. 32P-labelled probes for the
oestrogen receptor mRNA were synthesised by nick translation
(N-T) or by transcription using T3 or T7 polymerase of the Bam
H1 or Sal 1 linearised recombinant shown in Figure 1. The
positions of the 6.2kb oestrogen receptor mRNA and 28 and
18S ribosomal RNAs are marked.
Oestrogen Receptor RNA
20 Hourexposure
After an exposure time of only 20h, a 6.2kb RNA was
clearly visible in RNA prepared from MCF-7 cells, the
uterus, breast tumour 28 and the metastatic tumour in
lymph node 31. After a longer exposure of 14 days, the
oestrogen receptor mRNA of 6.2kb was detected in all the
samples apart from tumour 29. It is interesting that a lymph
node metastasis from this tumour did express oestrogen
receptor mRNA. Oestrogen receptor mRNA in these exam-
ples ranged from 0AU (tumour 29) to 34.3 AU (uterus).
Tumour 33 contained the lowest level of oestrogen receptor
mRNA detected (0.18AU): although the 6.2kb band is
barely visible on the photograph, it produced an easily
quantifiable peak by scanning densitometry of the original
autoradiograph.
The levels of oestrogen receptor mRNA and oestrogen
receptor protein in the uterus, MCF-7 cells, the primary
breast tumour samples and metastatic deposits are summar-
ised in Table I. The quantity of oestrogen receptor mRNA
detected in the 47 tumours varied from 0 to 1,993 AU. Only
six tumours (13%) expressed no detectable oestrogen recep-
tor mRNA while the other 41 (87%) expressed varying
levels. Of these, 9 expressed only small amounts of oestrogen
receptor mRNA (less than or equal to 1 AU, e.g. tumour
35), 26 contained intermediate amounts (between 1 and
100AU, e.g., tumour 28) and 6 contained large quantities (in
excess of 100AU). The largest quantity (1,993AU) was
present in a lobular carcinoma: this was six times higher
than the next greatest level. In one instance a primary
tumour and a recurrent tumour excised from the same
patient 9 months later were compared: both expressed
similar low/intermediate levels of oestrogen receptor mRNA
(4AU vs. 1.IAU).
Oestrogen receptor mRNA, tumour histology and
Bloom's grade
Thirty-nine of the tumours examined were primary ductal
carcinomas of the breast. These tumours were graded with
respect to differentiation using the method of Bloom &
Richardson (1959): 2 tumours were grade I, 11 were grade II
and 26 were grade III (this is an unusual sample, grade II
normally being the predominant group). A comparison of
oestrogen receptor and oestrogen receptor mRNA levels in
tumours of different histological grade is shown in Table II.
All 6 oestrogen receptor mRNA negative tumours were
grade III and 6 of the 7 ductal carcinomas with oestrogen
receptor mRNA levels of less than 1 AU were also grade III.
The median of the oestrogen receptor mRNA levels was
significantly lower for the grade III tumours than for the
grade I and II tumours (P<0.05).
Of the remaining non-ductal carcinomas, 2 were lobular
carcinomas: both expressed oestrogen receptor mRNA, one
expressing the highest level recorded (1,993AU) and the
Table I Levels of the oestrogen receptor and its mRNA in different
breast tumour samples, MCF-7 cells and a uterus.
MCF7 Tumour Lymph node Tumour Uterus
Figure 3 Oestrogen receptor probe hybridisation with Northern
transfers of MCF-7 cells, primary ductal carcinomas of breast,
breast carcinoma lymph node metastases and a uterus from a
premenopausal woman. Ten ug RNA from each of the tissue
samples and between 10 g and 0.01 jg (as indicated) of the
MCF-7 cell RNA were separated by gel electrophoresis, trans-
ferred to hybond-N membranes and hybridised with the single
stranded oestrogen receptor RNA probe. Twenty hour and 14
day exposures are shown. The probe identified a 6.2kb RNA
species in varying quantities in all but tumour 29. The amount of
oestrogen receptor RNA ranges from 0.18 AU (tumour 33) to
34.3 AU (uterus).
MCF-7 cells
Uterus
Primary tumours
(No tamoxifen
treatment)
Primary tumours
(Tamoxifen prior
to excision)
Lymph node metastases
(No tamoxifen
treatment)
Lymph node metastases
(Tamoxifen prior
to excision)
Oestrogen receptor
mRNA
(AU
20(1)
34.3 (1)
122.1 +61.4(33)t
7.8 +4.18(10)t
22.1(2)
7.2(1)
Oestrogen receptor
protein
(fmolmg- Iprotein)
100(1)
ND
84.3 +47.3 (26)t
3.9+2.4(9)t
47.5(2)
ND
ND=not determined; ( ) =no. samples; tmean +s.e.m.
14 Day exposure
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other expressing moderate quantities (76.7AU). The muci-
nous carcinoma also expressed moderate quantities of oes-
trogen receptor mRNA (19.3 AU) and the atypical medullary
carcinoma expressed a small amount (0.6AU). Oestrogen
receptor mRNA was present in the three lymph node
metastases examined (see above).
Menopausal status and oestrogen receptor mRNA
The oestrogen receptor and oestrogen receptor mRNA levels
in tumours from pre- and post-menopausal women are
shown in Table III. There was no significant difference in
median levels of oestrogen receptor mRNA between tumours
from the 14 different premenopausal women (age less than
50) and the 31 postmenopausal women (Chi square =0.437,
P>0.5). The percentages of tumours that express oestrogen
receptor mRNA in the two groups were the same. The
medians of the oestrogen receptor protein levels in tumours
from premenopausal and postmenopausal women were also
not significantly different (Chi square=1.246, P>0.25).
Correlation of oestrogen receptor mRNA with oestrogen
receptor protein
For 39 samples, oestrogen receptor protein levels determined
using a dextran-coated charcoal ligand binding assay were
available for comparison with the mRNA levels. Using this
assay any values below 5 fmol oestrogen receptor protein/mg
cytosol protein were considered negative. A graphical
representation of this comparison is shown in Figure 4. The
oestrogen receptor protein was not detected in 21 tumours
(53%) whereas the oestrogen receptor mRNA was absent in
only 6 (15%). In 14 of the remaining 15 receptor protein
negative tumours oestrogen receptor mRNA was present at
relatively low levels (all less than 13.3AU). The remaining
member of this group of receptor protein negative tumours
contained the highest level of receptor RNA detected
(1,993 AU).
One tumour contained very high and two tumours rela-
tively high levels of oestrogen receptor protein but only low
levels of the mRNA. These examples may reflect tumour
heterogeneity with respect to oestrogen receptor expression.
Overall, the oestrogen receptor protein levels correlated
significantly with oestrogen receptor mRNA levels and
Spearman's Correlation Coefficient was calculated to be
0.74, P<0.0001.
Tamoxifen and oestrogen receptor mRNA
A number of patients had been treated with tamoxifen prior
to tumour excision (Figure 4). Tamoxifen, while unlikely to
affect the results of oestrogen receptor mRNA estimation,
has been cited as a cause of falsely low or negative oestrogen
receptor protein estimations (Hull et al., 1980). In the
current series, the effects of tamoxifen on receptor protein
estimation was not clear cut and in only one instance was
there an unexpectedly low oestrogen receptor protein level in
the face of high mRNA levels. Of the remaining cases, 3
expressed low levels of oestrogen receptor mRNA but no
protein (possibly reflecting the increased sensitivity of the
mRNA assay), 1 expressed low levels of mRNA but high
levels of protein, 2 expressed high levels of mRNA and
protein, and 2 contained no RNA or protein. Overall, there
were not significantly fewer oestrogen receptor positive
tumours in the group of patients treated with tamoxifen (Chi
squared test; P>0.1).
Discussion
In this paper we describe the isolation of high quality RNA
and subsequent detection of oestrogen receptor mRNA in a
series of breast tumours. We detected hybridisation to a
single oestrogen receptor RNA band of approximately 6.2kb
in extracts of RNA prepared from MCF-7 breast cancer
cells, all the positive breast tumours and a uterus from a
premenopausal woman. A 6.2 kb RNA was detected pre-
viously in MCF-7 cell RNA (Walter et al., 1985) whereas
others detected a 4.2kb oestrogen receptor RNA in the
uterus from a premenopausal woman (Parl et al., 1987). We
did not detect the 3.7kb oestrogen receptor RNA found by
Barrett-Lee et al. (1987) in both MCF-7 cell and breast
tumour RNA.
Estimation of the level of the oestrogen receptor mRNA
in Northern transfers of tumour extracts is a highly sensitive
method of measuring oestrogen receptor mRNA levels. The
presence of a single, well-defined hybridisation band of
6.2kb is unequivocal evidence of the presence of oestrogen
receptor mRNA and problems of non-specific background
hybridisation are largely eliminated, allowing confident
determination, even at low levels of oestrogen receptor
expression. The notoriously unstable nature of mRNA does
present problems, but RNA degradation was minimised by
prompt handling and cryo-preservation of tumour tissue,
coupled with scrupulous preparation of glassware, chemicals
and instruments.
Measurement of oestrogen receptor mRNA levels was
more sensitive than the ligand binding oestrogen receptor
protein assays in this study. Great variation in the propor-
tion of tumours expressing the oestrogen receptor protein
has been reported (Thorpe, 1987). Of the 45 breast tumours
from different patients included in this study, 39 (87%)
contained detectable quantities of oestrogen receptor mRNA.
This figure is even more remarkable when the large numbers
Table II Comparison of oestrogen receptor and oestrogen receptor mRNA levels in
tumours graded according to Bloom and Richardson (1959).
Oestrogen receptor Oestrogen receptor
mRNA protein
(AU (fmolmg-' protein)
Mean Median No. Mean Median No.
Grade I and 11 67.9+28.5 32.7a 13 79.2+63.2 7.2 8
Grade III 43.6+ 19.9 1.4a 26 67.6+49.9 0 21
aP<0.05.
Table III Comparison of oestrogen receptor and oestrogen receptor mRNA levels in
tumours from premenopausal and postmenopausal women.
Oestrogen receptor Oestrogen receptor
mRNA protein
(AU (fmolmg-' protein)
Mean Median No. Mean Median No.
Premenopausal 63.6+30.7 20.7 14 87.4+45.9 39 11
Postmenopausal 105.4+64.8 64.8 31 52.8 +49.9 0 26604 J.A. HENRY et al.
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Figure 4 Correlation between oestrogen receptor mRNA and
protein levels. C =patients pretreated with tamoxifen. mRNA
and protein levels were compared using Spearman's Correlation
Coefficient, rs=0.74, P<0.0001, n=39.
of poorly differentiated (grade III) tumours included in this
study are considered. In the 37 different tumours where the
levels of the oestrogen receptor and mRNA were compared,
using 5fmol oestrogen receptor protein/mg cytosolic protein
as the cut off for receptor positivity, only 46% were
oestrogen receptor protein positive. This reflects a genuine
difference in sensitivity. The incidence of oestrogen receptor
positivity, although low in comparison to some other studies,
can be attributed to the following features of the population
studied: the disproportionately high number of grade III
tumours; selection of patients aged over 70 on grounds of
failure to respond to tamoxifen (patients in this group who
responded to tamoxifen were not treated surgically hence
reducing the number of likely oestrogen receptor positive
subjects); and selection of material principally from larger
tumours (only these tumours yielded sufficient tissue for
both assays).
The functional significance of the expression of low levels
of oestrogen receptor remains to be established, particularly
with regard to determining response to antioestrogen
therapy. Such low (and previously undetectable) levels of
oestrogen receptor may account for the seemingly anomalous
remission following antioestrogen therapy seen in 5 to 10%
of apparently oestrogen receptor-negative breast tumours
(McGuire et al., 1975). Low levels of oestrogen receptor
expression may be due to uniform low levels of oestrogen
receptor expression throughout a tumour or may reflect
tumour heterogeneity, with small areas of otherwise negative
tumours expressing high levels of oestrogen receptor. This
issue remains to be settled although there is evidence to
support the latter contention (van Netten et al., 1985): high
resolution in situ hybridisation techniques using sensitive
probes may be of value. There is also heterogeneity of
oestrogen receptor expression between primary tumours and
their lymph node metastases. Extracts of one primary breast
tumour (tumour 29, figure 3) contained no oestrogen recep-
tor mRNA, yet a lymph node metastasis from the same
tumour did. Similar disparities between the oestrogen recep-
tor levels in primary tumours and lymph node metastases
have been reported previously (Rosen et al., 1977), although
the converse situation arises more frequently (Castagnetta et
al., 1987). Such heterogeneity may also explain the objective
response to antioestrogen therapy seen in a small proportion
of apparently oestrogen receptor-negative tumours.
One of the two lobular carcinomas examined expressed
extremely high levels of oestrogen receptor mRNA
(1,993AU) in the absence of detectable oestrogen receptor
protein (Figure 4). While this may be explained by extreme
tumour heterogeneity, a further intriguing possibility is that
in this tumour the oestrogen receptor gene is transcribed but
the RNA is not translated. The exceptionally high level of
oestrogen receptor mRNA may be due to loss of some
normal feedback mechanism dependent on synthesis of
receptor protein.
Oestrogen receptor mRNA expression was also considered
with regard to tumour histology, differentiation and meno-
pausal status. Oestrogen receptor mRNA was detected in all
of the histological sub-types examined, in agreement with the
receptor protein findings of Rosen et al. (1978). When
tumour differentiation was considered all the oestrogen
receptor mRNA negative ductal carcinomas and all but one
of those expressing only very low levels of oestrogen receptor
mRNA (<1 AU) belonged to grade III of Bloom &
Richardson's classification (1959): the median of the oestro-
gen receptor mRNA levels was significantly lower in this
group (Table II). This trend is in agreement with other
studies of oestrogen receptor protein expression (McCarty et
al., 1980, Furmanski et al., 1980, Hawkins et al., 1987). As
oestrogen receptor expression is a differentiated feature of
breast epithelial cells, it is attractive to hypothesise that its
expression should decline with loss of morphological features
of differentiation. Median oestrogen receptor mRNA and
protein levels were similar in tumours from both premeno-
pausal and postmenopausal women: other studies of protein
levels (Clark et al., 1983; Hawkins et al., 1987) and mRNA
levels (Barrett-Lee et al., 1987) found higher levels in
tumours from post-menopausal patients. The reason for the
differences between these studies and the present work are
not clear.
Determination of the oestrogen receptor mRNA content
using Northern transfers of tumour RNA offers a new
approach to the investigation of oestrogen receptor expres-
sion and status in breast cancer. This technique is highly
sensitive and oestrogen receptor may be detectable in a
higher proportion of breast tumours than previously
thought. The biological significance of low levels of oestro-
gen receptor expression remains to be determined.
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